百令胶囊联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床研究  

Clinical Study on Corbrin Capsule Combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation in Treatment of Bronchial Asthma

作　　者：李剑[1] 赵晓宇[1] LI Jian;ZHAO Xiaoyu(Dalian University Affiliated Xinhua Hospital,Dalian 116021,China)

机构地区：[1]大连大学附属新华医院,辽宁大连116021

出　　处：《中国医学创新》2020年第31期18-22,共5页Medical Innovation of China

摘　　要：目的:观察百令胶囊联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床效果和安全性。方法:选取2018年6月-2019年6月在大连大学附属新华医院呼吸科就诊的轻到中度支气管哮喘患者72例,按照随机数字表法分为对照组和治疗组,各36例。对照组患者给予沙美特罗替卡松粉吸入剂治疗,治疗组患者在对照组的基础上给予百令胶囊口服。两组患者均按需使用速效β2受体激动剂万托林气雾剂。比较两组患者的临床疗效,同时比较两组患者治疗前后的炎症因子水平、血嗜酸性粒细胞比例、FeNO、肺功能和哮喘控制测试(ACT)评分情况。结果:治疗后,治疗组总有效率为97.22%,高于对照组的86.11%,差异有统计学意义(P<0.05)。治疗后,两组患者IL-4、IL-5、IL-13水平和血嗜酸性粒细胞比例、FeNO均显著低于治疗前,且治疗后治疗组上述指标均明显低于对照组(P<0.05)。治疗后,两组患者FEV1%pred、PEF%pred及ACT评分均显著高于治疗前,且治疗后治疗组上述指标均明显高于对照组(P<0.05)。结论:百令胶囊联合沙美特罗替卡松粉吸入剂治疗支气管哮喘临床效果好,可有效减轻哮喘气道炎症,明显改善肺功能,提高哮喘临床控制水平,值得临床推广应用。Objective:To observe the clinical efficacy and safety of Corbrin Capsule combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation in treatment of bronchial asthma.Method:From June 2018 to June 2019,72 patients with mild to moderate bronchial asthma were selected in the department of respiratory,Dalian University Affiliated Xinhua Hospital.According to the expression of random numbers,the patients were divided into control group and treatment group,36 cases each.The patients in the control group were given Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation.The patients in the treatment group were given Corbrin Capsule on the basis of the control group.The patients in the two groups were given short-acting β2-agonists Ventolin according to the need.Clinical outcomes were compared between the two groups,as well as inflammatory factor levels,blood eosinophils ratio,FeNO,lung function,and asthma control test (ACT) scores before and after treatment were compared between the two groups.Result:After treatment,the total effective rate of the treatment group was 97.22%,higher than 86.11% of the control group,the difference was statistically significant (P<0.05).After treatment,the levels of IL-4,IL-5,IL-13,eosinophils and FeNO in both groups were significantly lower than those before treatment,and those in the treatment group were significantly lower than those in the control group after treatment (P<0.05).After treatment,FEV1%pred,PEF%pred and ACT scores in both groups were significantly higher than those before treatment,and the above indicators in the treatment group were significantly higher than those in the control group after treatment (P<0.05).Conclusion:Corbrin Capsule combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation has good clinical effect in treatment of bronchial asthma,and can effectively relieve airway inflammation,obviously improve pulmonary function and raise the level of asthma control,it is worthy of clinical application.

关 键 词：百令胶囊 沙美特罗替卡松粉吸入剂 支气管哮喘 气道炎症 肺功能 ACT评分 

分 类 号：R562.25[医药卫生—呼吸系统]